Wang Xiaoyan

Dr. Wang Xiaoyan


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

16 December 2025 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
BLBoyuan Liu
Boyuan Liu
JQJunsen Qin
Junsen Qin
SZShan Zheng
Shan Zheng
JZJiaxin Zhang
Jiaxin Zhang
XHXuemei Hu
Xuemei Hu
YLYan Liu
Yan Liu
Objective: This study aims to investigate the antitumour mechanism of ergosta-4,6,8(14),22-tetraen-3-one (ETO), extracted from Pholiota adiposa, in H22 tumour-bearing mice through integrated metabolomics and gut microbiota systems analysis. Methods: After establishing the H22 tumor mouse model, we performed serum metabolomics through nontargeted UHPLC-HRMS and conducted gut microbiota profiling. Result: ETO exhibited significant antitumor effects, with tumor inhibition rates of 59.74% (low dose) and 76.10% (high dose).Untargeted metabolomics revealed that molecules downstream of the tricarboxylic acid cycle, arachidonic acid and linoleic acid were upregulated. Gut microbiota analysis revealed ETO-mediated enrichment of beneficial bacteria (Firmicutes and Lactobacillus) and suppression of the harmful bacterial species Bartonella. Integrative analysis demonstrated a negative correlation between indole-3-acetonitrile and Bartonella. Conclusion: ETO can inhibit the growth of tumor cells, and its effect on liver and kidney damage is less than that of CTX. Linoleate, and L-tryptophan emerged as potential therapeutic targets, while Firmicutes and Lactobacillus enrichment suggests gut microbiota-mediated antitumor activity, providing novel insights for hepatocellular carcinoma treatment.

4 November 2025 in Fitoterapia
Verified
Journal Article
Closed access
ZHZhijie He
Zhijie He
ZTZhongyu Tan
Zhongyu Tan
YYYue Yin
Yue Yin
LZLunrong Zhang
Lunrong Zhang
BBBo Bi
Bo Bi
JBJingshan Bao
Jingshan Bao